Search Results

Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, and Korean non profit research institute Institut Pasteur Korea announced that they have jointly developed new lead compounds effective in treating resistant tuberculosis (TB).

Standigm Inc. (“Standigm”), the leading workflow artificial intelligence (AI) drug discovery company, today announced the appointment of Chief Business Officer Carl Foster.

Standigm Inc. (“Standigm”), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research.

Standigm Inc. (“Standigm”), announced today that the company had filed PCT (“Patent Cooperation Treaty”) patent application covering AI-driven repurposed drugs for primary mitochondrial disease through successful research collaboration with a US hospital, which has world-renowned expertise in the mitochondrial field.

Standigm Inc., the leading workflow artificial intelligence drug discovery company, announced that the company had established a Synthetic Research Center in the headquarters of SK Chemicals Co., Ltd, a life science and green chemicals company.

Pavilion Capital invests $10 M in Standigm, the specialized workflow AI drug discovery company.

Standigm Inc., a leading Korean Artificial Intelligence company for drug discovery, announces that it has closed $44.5 million in a pre-IPO funding round co-led by SKS PE and Daishin Private Equity.

Standigm Inc. (“Standigm”), an artificial intelligence (AI)-based drug discovery company and SK Chemicals Co., Ltd. (“SK Chemicals”), a life science and green chemicals company, announce today that they have successfully found a new rheumatoid arthritis indication for an FDA-approved drug and have filed a patent.

Excelra, a global data science and data analytics company, today announced its collaboration with Standigm Inc., a company using artificial intelligence (AI) technology for drug discovery and development.

Standigm and SK holdings C&C Release an AI-Based Target Identification Platform, iCLUE&ASK ™ , to Accelerate Drug Discovery Process SEOUL, South Korea--( BUSINESS WIRE )-- Standigm Inc. (“Standigm”), an artificial intelligence (AI)-based drug discovery company, and SK holdings C&C, Co., Ltd. (“SK holdings C&C”), a specialized Information and communications technology company, announced today that they opened their AI-based target identificat